Apexigen to Participate in the 2021 Wedbush PacGrow Healthcare Conference SAN CARLOS, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...

Apexigen to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...

Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer SAN CARLOS, Calif. and COPENHAGEN, Denmark, June 16, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of...

Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody, Sotigalimab (APX005M), in Combination Therapy for Metastatic Pancreatic Cancer at the ASCO 2021 Annual Meeting Clinical benefit observed in 1-year overall survival with addition of sotigalimab to standard of care gemcitabine/nab-paclitaxel; 48.1% as compared to the 35% historical standard of care control ...